NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Forecast, Price & News $1.12 +0.02 (+1.82%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$1.06▼$1.1350-Day Range$1.07▼$1.3852-Week Range$0.67▼$2.04Volume786,081 shsAverage Volume847,085 shsMarket Capitalization$195.28 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Rigel Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside413.4% Upside$5.75 Price TargetShort InterestHealthy2.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.26) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector729th out of 965 stocksPharmaceutical Preparations Industry340th out of 453 stocks 3.4 Analyst's Opinion Consensus RatingRigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.75, Rigel Pharmaceuticals has a forecasted upside of 413.4% from its current price of $1.12.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.19% of the outstanding shares of Rigel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 2.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RIGL. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Rigel Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions63.45% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.26) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Rigel Pharmaceuticals (NASDAQ:RIGL) StockRigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Read More RIGL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RIGL Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comRigel to Present at the 2023 Cantor Global Healthcare ConferenceAugust 30, 2023 | finance.yahoo.comRigel to Participate in Upcoming September Investor ConferencesSeptember 22, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 2, 2023 | finance.yahoo.comQ2 2023 Rigel Pharmaceuticals Inc Earnings CallAugust 2, 2023 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 1, 2023 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q2 Loss decreases, beats estimatesAugust 1, 2023 | finance.yahoo.comRigel Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 25, 2023 | finance.yahoo.comRigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business UpdateSeptember 22, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.July 5, 2023 | finance.yahoo.comInvestors in Rigel Pharmaceuticals (NASDAQ:RIGL) have unfortunately lost 55% over the last five yearsJune 7, 2023 | finance.yahoo.comBullish Rigel Pharmaceuticals Insiders Rewarded As Their Investment Rises To US$1.5mJune 7, 2023 | finance.yahoo.comBullish Rigel Pharmaceuticals Insiders Rewarded As Their Investment Rises To US$1.5m \June 7, 2023 | finance.yahoo.comRigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AMLJune 6, 2023 | msn.comRigel spikes after peer reviewed data on leukemia drugJune 6, 2023 | finance.yahoo.comRigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood AdvancesJune 1, 2023 | finance.yahoo.comRigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual MeetingMay 31, 2023 | finance.yahoo.comRigel to Present at the Jefferies 2023 Global Healthcare ConferenceMay 4, 2023 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2023 Earnings Call TranscriptMay 3, 2023 | msn.comHC Wainwright & Co. Reiterates Rigel Pharmaceuticals (RIGL) Buy RecommendationMay 3, 2023 | finance.yahoo.comQ1 2023 Rigel Pharmaceuticals Inc Earnings CallMay 2, 2023 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q1 Loss decreases, beats estimatesApril 26, 2023 | finance.yahoo.comEarnings Preview: Pacira (PCRX) Q1 Earnings Expected to DeclineApril 25, 2023 | finance.yahoo.comRigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseApril 25, 2023 | finance.yahoo.comRigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business UpdateApril 21, 2023 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is favoured by institutional owners who hold 55% of the companyApril 16, 2023 | finance.yahoo.com12 Best Low-Priced Growth Stocks To BuyMarch 9, 2023 | finance.yahoo.comRigel Pharmaceuticals Full Year 2022 Earnings: Beats ExpectationsSee More Headlines Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RIGL Company Calendar Last Earnings8/01/2023Today9/21/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RIGL CUSIP76655960 CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees155Year Founded1996Price Target and Rating Average Stock Price Forecast$5.75 High Stock Price Forecast$15.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+413.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,570,000.00 Net Margins-29.83% Pretax Margin-29.83% Return on EquityN/A Return on Assets-30.80% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio2.05 Sales & Book Value Annual Sales$120.24 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-14.00Miscellaneous Outstanding Shares174,360,000Free Float159,717,000Market Cap$195.28 million OptionableOptionable Beta0.69 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Raul R. Rodriguez (Age 62)Pres, CEO & Director Comp: $1.09MMr. Dean L. Schorno CPA (Age 60)Exec. VP & CFO Comp: $696.67kMr. Raymond J. Furey J.D. (Age 55)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $593.46kMr. David A. Santos (Age 60)Exec. VP & Chief Commercial Officer Comp: $681.63kMr. Joseph Lasaga (Age 48)Exec. VP of Corp. Devel. Ms. Julie PatelSr. VP of HRDr. Esteban S. Masuda (Age 61)Exec. VP of Research Mr. Tarek SallamVP of MarketingMore ExecutivesKey CompetitorsXOMANASDAQ:XOMAEmergent BioSolutionsNYSE:EBSMerrimack PharmaceuticalsNASDAQ:MACKVerastemNASDAQ:VSTMVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 53,212 shares on 9/21/2023Ownership: 0.026%Nuveen Asset Management LLCSold 292,841 shares on 8/16/2023Ownership: 1.409%Alliancebernstein L.P.Bought 16,840 shares on 8/15/2023Ownership: 0.188%Integrated Wealth Concepts LLCBought 10,000 shares on 8/15/2023Ownership: 0.011%Citadel Advisors LLCSold 2,500 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RIGL Stock - Frequently Asked Questions Should I buy or sell Rigel Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RIGL shares. View RIGL analyst ratings or view top-rated stocks. What is Rigel Pharmaceuticals' stock price forecast for 2023? 4 equities research analysts have issued 12 month price targets for Rigel Pharmaceuticals' stock. Their RIGL share price forecasts range from $2.00 to $15.00. On average, they expect the company's stock price to reach $5.75 in the next year. This suggests a possible upside of 413.4% from the stock's current price. View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts. How have RIGL shares performed in 2023? Rigel Pharmaceuticals' stock was trading at $1.50 at the start of the year. Since then, RIGL stock has decreased by 25.3% and is now trading at $1.12. View the best growth stocks for 2023 here. When is Rigel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our RIGL earnings forecast. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its earnings results on Tuesday, August, 1st. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. The biotechnology company had revenue of $26.89 million for the quarter, compared to the consensus estimate of $26.02 million. During the same quarter in the previous year, the company earned ($0.08) earnings per share. What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO? 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). What is Rigel Pharmaceuticals' stock symbol? Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL." Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.38%), Acadian Asset Management LLC (2.63%), Assenagon Asset Management S.A. (2.09%), State Street Corp (2.02%), Geode Capital Management LLC (1.95%) and Nuveen Asset Management LLC (1.41%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rigel Pharmaceuticals' stock price today? One share of RIGL stock can currently be purchased for approximately $1.12. How much money does Rigel Pharmaceuticals make? Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $195.28 million and generates $120.24 million in revenue each year. The biotechnology company earns $-58,570,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. How many employees does Rigel Pharmaceuticals have? The company employs 155 workers across the globe. How can I contact Rigel Pharmaceuticals? Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101. This page (NASDAQ:RIGL) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.